Is a complete GYRE research report available?

No complete published report is available for Gyre Therapeutics, Inc. (GYRE) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

Gyre Therapeutics, Inc. (GYRE)

NASDAQ: GYRE · USD

$5.81

+0.17 (+3.0%)· Recorded snapshot

Coverage state: Market snapshot only — no published research

Market snapshot recorded 2026-07-31 02:00 UTC. No published research is attached to this ticker. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate the first GYRE analysis

Start the full research workflow when this ticker is ready in our data system.

Market cap	647.8M
Revenue (ttm)	117M
Net income (ttm)	-6.4M
EPS (ttm)	-$0.08
Shares out	111.5M
Volume	45,636
Beta	4.77
Price target	$18.7	+221.3%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 117M
Net income (ttm): -6.4M
EPS (ttm): -$0.08
Market cap: 647.8M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	27.4B	36.9x	5.7x	96.6%	+47.5%	-37.8%	Strong Buy
ARGX	argenx SE	53.8B	31.3x	10.1x	50.6%	+58.8%	+45.7%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All GYRE indicators

Market & fundamental data

Available fields

210

Groups with data

Currency

USD

Showing 210 of 210 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001124105
Company name	Gyre Therapeutics, Inc.
Country	United States
Country code	US
Cusip	403783103
Employees	625
Employees Change	46%
Employees Change Percent	7.94
Enterprise value	$598.8M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
Isin	US4037831033
Last refreshed	2026-07-31
Market cap	$647.8M
Market cap category	Small-Cap
Price	$5.81
Price currency	USD
Rev Per Employee	187,278.4x
Sector	Healthcare
Sector PE	45.21
Sector PE Fwd	23.64
Sic	2834
Symbol	GYRE
Website	https://www.gyretx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-0.98%
EV Sales Forward	7.51x
EV/EBITDA	241.73x
EV/FCF	194.85x
EV/Sales	5.12x
FCF yield	0.47%
P/B ratio	5.24x
P/S ratio	5.53x
PS Forward	8.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	-0.12%
EBITDA Margin	2.12%
FCF margin	2.63%
Gross margin	95.09%
Gross Profit	$111.3M
Gross Profit Growth	14.93%
Gross Profit Growth Q	0.6%
Gross Profit Growth3 Y	3.78%
Net Income	$-6.4M
Net Income Growth Years	0%
Pretax Margin	0.48%
Profit Margin	-5.44%
Profit Per Employee	$-10,179
Profitable Years	2
ROA	1.03
ROCE	-0.1
ROE	-3.08
ROIC	-17.79

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	-20.42%
EPS Growth Years	0
FCF Growth3 Y	-29.85%
OCF Growth3 Y	-34.03%
Revenue Growth	16.3x
Revenue Growth Q	2.09x
Revenue Growth Quarters	4x
Revenue Growth Years	1x
Revenue Growth3 Y	3.87x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.8
Assets	$162M
Cash	$49.8M
Current Assets	$91.7M
Current Liabilities	$19.8M
Debt	$823,000
Debt EBITDA	$0.33
Debt Equity	$0.01
Debt FCF	$0.27
Equity	$137M
Liabilities	$25M
Long Term Assets	$70.3M
Long Term Liabilities	$5.2M
Net Cash	$49M
Net Cash By Market Cap	$7.56
Net Cash Growth	73.06%
Net Debt EBITDA	$-19.78
Net Debt Equity	$-0.36
Net Debt FCF	$-15.94
Tangible Book Value	$96.7M
Tangible Book Value Per Share	$1.06
WACC	30.47

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	4.64
Inventory Turnover	0.6
Net Working Capital	$22.9M
Quick ratio	3.68
Working Capital	$71.9M
Working Capital Turnover	$1.93

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	11.33%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	-20.41%
200-day SMA	7.32
50-day SMA	6.19
50-day SMA vs 200-day SMA	50under200
All Time High	30.4
All Time High Change	-80.89%
All Time High Date	2023-12-21
All Time Low	5.44
All Time Low Change	6.8%
All Time Low Date	2026-06-02
ATR	0.31
Beta	4.77
Beta1y	1.42
Beta2y	1.82
Ch YTD	-17.71
High	5.95
High52	9.42
High52 Date	2025-10-16
High52ch	-38.32%
Low	5.72
Low52	5.44
Low52 Date	2026-06-02
Low52ch	6.8%
Ma50ch	-6.14%
Price vs 200-day SMA	-20.63%
RSI	41.6
RSI Monthly	45.54
RSI Weekly	38.94
Sharpe ratio	-0.16x
Sortino ratio	-0.14
Total Return	11.33%
Tr YTD	-17.71
Tr1m	-9.92%
Tr1w	-3.33%
Tr3m	-20.95%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	3
Analyst Count Top	0
Analyst Ratings	Strong Buy
Earnings EPS Estimate	$-0.06
Earnings Revenue Estimate	26,440,000x
Earnings Revenue Estimate Growth	-1.24x
Operating Income	$2.4M
Operating Income Growth	-76.84
Operating Income Growth3 Y	-37.42
Operating margin	2.06
Price target	$18.67
Price Target Change	$221

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	41,396,652%
Float Percent	37.13%
Shares Insiders	5.46%
Shares Institutions	3.07%
Shares Out	111,488,849
Shares Qo Q	0.21%
Shares Yo Y	-11.33%
Short Float	4.94%
Short Ratio	17.38
Short Shares	1.83

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-6.2M
Adjusted OCF	-4,914,000
Average Volume	65,406.1x
Bv Per Share	1.11
CAPEX	$-1.2M
Ch1m	-9.92
Ch1w	-3.33
Ch1y	-20.41
Ch3m	-20.95
Ch6m	-29.23
Change	3.01%
Change From Open	1.57
Close	5.64
Days Gap	1.42
Depreciation Amortization	2,657,000
Dollar Volume	265,145.2
Earnings Date	2026-08-11
Earnings Time	amc
EBIT	$-141,000
EBITDA	$2.5M
EPS	$-0.08
F Score	5
FCF	$3.1M
FCF EV Yield	0.51x
FCF Per Share	$0.03
Financing CF	23,055,000
Fiscal Year End	December
Founded	2,002
Income Tax	$4.3M
Investing CF	-5,496,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-07
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-03-13
Ma150	7.15
Ma150ch	-18.74%
Ma20	6.35
Ma20ch	-8.48%
Net CF	22,456,000
Next Earnings Date	2026-08-10
Open	5.72
Optionable	Yes
P FCF Ratio	210.8
P OCF Ratio	150
Position In Range	39.13
Ppne	23,572,000
Price Date	2026-07-30
Price EBITDA	$262
Ptbv Ratio	6.7
Relative Volume	0.7x
Revenue	117,049,000x
SBC By Revenue	7.89x
Share Based Comp	9,233,000
Tax By Revenue	3.65x
Tax Rate	758.16%
Tr6m	-29.23%
Us State	California
Volume	45,636
Z Score	18

Gyre Therapeutics, Inc. (GYRE)

Coverage state: Market snapshot only — no published research

Generate the first GYRE analysis

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · GYRE

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All GYRE indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on GYRE

Frequently asked questions